Endocyte raises another $100M in stock offering

Back to TopCommentsE-mailPrintBookmark and Share

Endocyte Inc. raised $101.8 million in a public stock offering, the West Lafayette-based drugmaker announced last week, giving it more cash to keep developing its stable of cancer drugs.

The biotech drug firm said in December it would sell up to $60 million in stock “from time to time". But Endocyte was able to raise far more because its stock shot up March 21 after its first drug, Vynfinit, passed a critical hurdle to get onto the market in Europe and the drug showed promise in a trial of lung cancer patients.

Those announcements even sparked talk of Endocyte being acquired by a large pharmaceutical company.

“This could be a machine that produces multiple drugs,” Simos Simeonidis, a New York-based analyst at Cowen, told Bloomberg News. “I think definitely big pharma or big biotech would be interested in bringing this in house.”

Even so, investors were disappointed by the price of Endocyte’s public offering of $21 per share. The price was announced after markets closed March 25, when Endocyte shares closed at $27.19 apiece. They fell more than 19 percent the rest of the week.

The additional funds now mean Endocyte has $225 million to perform clinical trials and other R&D work on its drugs, as well as to build the commercial team it needs to launch its drug in Europe.

In 2013, Endocyte burned through $83 million on R&D and administrative costs, although more than $20 million of that bill was paid by New Jersey-based Merck & Co. Inc., which has licensed the rights to Vynfinit.

Merck will handle sales and marketing of Vynfinit, if the drug receives final approval from the European Union. But Endocyte will handle sales of a companion diagnostic agent called Folcepri, which is key for identifying patients who will benefit from Vynfinit.

Endocyte’s technology was first developed at Purdue University by chemist Philip Low. Since some cancer tumors have an abundance of “receptors” that bind easily with the vitamin folate, Low figured a powerful chemotherapy drug could be combined with a folate molecule so it would target only cancerous cells and not healthy cells.

That allows Endocyte’s drugs to be more deadly to cancer without more serious side effects than patients can tolerate with traditional chemotherapy agents. The company is also developing drugs to treat other diseases, such as inflammation.

Endocyte, founded in 1995, went public in 2011, raising $145 million in two public stock offerings.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. How can any company that has the cash and other assets be allowed to simply foreclose and not pay the debt? Simon, pay the debt and sell the property yourself. Don't just stiff the bank with the loan and require them to find a buyer.

  2. If you only knew....

  3. The proposal is structured in such a way that a private company (who has competitors in the marketplace) has struck a deal to get "financing" through utility ratepayers via IPL. Competitors to BlueIndy are at disadvantage now. The story isn't "how green can we be" but how creative "financing" through captive ratepayers benefits a company whose proposal should sink or float in the competitive marketplace without customer funding. If it was a great idea there would be financing available. IBJ needs to be doing a story on the utility ratemaking piece of this (which is pretty complicated) but instead it suggests that folks are whining about paying for being green.

  4. The facts contained in your post make your position so much more credible than those based on sheer emotion. Thanks for enlightening us.

  5. Please consider a couple of economic realities: First, retail is more consolidated now than it was when malls like this were built. There used to be many department stores. Now, in essence, there is one--Macy's. Right off, you've eliminated the need for multiple anchor stores in malls. And in-line retailers have consolidated or folded or have stopped building new stores because so much of their business is now online. The Limited, for example, Next, malls are closing all over the country, even some of the former gems are now derelict.Times change. And finally, as the income level of any particular area declines, so do the retail offerings. Sad, but true.